Prior authorization is a requirement from insurance companies that doctors get advance approval before prescribing certain dementia medications. In the context of Alzheimer’s disease and other dementias, prior authorization means your doctor cannot simply write a prescription for newer anti-amyloid drugs or other specialty dementia treatments—they must first submit documentation to your insurance company, wait for a response, and often provide clinical evidence that you meet specific criteria before the medication can be dispensed. This process sits between your doctor’s diagnosis and your ability to start the drug, which is a critical distinction because time matters in dementia treatment.
For many newer dementia drugs, prior authorization has become standard practice. When a neurologist or primary care doctor wants to prescribe lecanemab (Leqembi), an anti-amyloid monoclonal antibody approved for early Alzheimer’s disease, they must send detailed clinical information to the patient’s insurance company and wait—sometimes days, sometimes weeks—for approval. During that waiting period, a patient with early cognitive decline is not receiving the medication, even though their doctor has already determined they are a candidate and need it. A patient with a diagnosis of mild cognitive impairment who could benefit from lecanemab might receive a prescription on a Monday, but the drug won’t actually be dispensed until the following Friday because the insurance company required three additional days to review the claim, check the patient’s cognitive testing scores, and confirm that the specific dose and administration schedule meet their coverage criteria.
Table of Contents
- Why Do Insurance Companies Require Prior Authorization for Dementia Drugs?
- Which Dementia Drugs Have the Strictest Prior Authorization Requirements?
- How Much Time Does Prior Authorization Add to Starting Dementia Treatment?
- What Can Caregivers and Patients Do to Speed Up Prior Authorization?
- What Happens If Prior Authorization Is Denied?
- Are There Alternative Ways to Access Dementia Drugs Without Prior Authorization?
- How Does Prior Authorization Pressure Doctors to Practice Differently?
- Frequently Asked Questions
Why Do Insurance Companies Require Prior Authorization for Dementia Drugs?
insurance companies implement prior authorization for dementia medications primarily to manage escalating drug costs and to ensure medications are prescribed only to patients who truly meet clinical criteria. Newer anti-amyloid monoclonal antibodies like lecanemab and donanemab cost tens of thousands of dollars per year, and insurers use prior authorization as a gating mechanism to prevent use in patients with more advanced dementia or other conditions where the drugs have not been shown to be effective. The logic is straightforward from a cost perspective: if the drug is only appropriate for people with mild cognitive impairment or mild dementia, then prior authorization catches prescriptions written outside those boundaries and prevents unnecessary spending. The clinical rationale also matters.
These newer dementia drugs come with requirements for baseline cognitive testing, brain imaging showing amyloid buildup, and sometimes genetic testing for the APOE4 gene. Prior authorization allows insurers to verify that a patient has actually had these tests done, rather than trusting that the doctor ordered them. For lecanemab, the drug also carries a warning about a serious adverse effect called amyloid-related imaging abnormalities (ARIA), and insurers use prior authorization to confirm that baseline MRI imaging has been completed before the drug is approved, reducing the risk of serious harm. However, there is a significant gap between the insurance company’s stated clinical criteria and what is actually documented or what the patient’s test results show. A patient might have a recent cognitive test, an MRI showing amyloid, and a clear diagnosis—yet the insurance company may request additional documentation from the neurologist, ask for a second opinion, or deny the request based on an interpretation of the cognitive test scores that differs from the neurologist’s interpretation.
Which Dementia Drugs Have the Strictest Prior Authorization Requirements?
The newest anti-amyloid monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla), both approved by the FDA in 2023–2024—almost universally require prior authorization from all major insurance plans. These drugs are restricted to patients with mild cognitive impairment or mild dementia with documented amyloid pathology, and insurers enforce these restrictions aggressively because of the high cost, the novelty of the mechanism, and ongoing questions about real-world effectiveness. Lecanemab, for example, showed an 27% slowing of cognitive decline in clinical trials over 18 months—a real but modest effect—and insurance companies scrutinize whether this benefit justifies the cost for individual patients. Other dementia-related medications may have prior authorization requirements depending on the insurance plan and the specific indication.
Cholinesterase inhibitors like donepezil (Aricept) and rivastigmine rarely require prior authorization because they are older, generic, and inexpensive. But newer treatments, or use of older drugs for off-label indications, frequently trigger the requirement. Some insurance plans require prior authorization for memantine (Namenda) when prescribed in combination with a cholinesterase inhibitor, despite this being standard clinical practice for moderate to severe Alzheimer’s disease. A major limitation is that Medicare and Medicaid coverage policies for prior authorization vary by state and by the specific Part D plan, so there is no single answer for what “requires prior authorization.” A patient with traditional Medicare might have prior authorization waived for lecanemab because their supplemental insurance covers it, while a patient with Medicare Advantage might face strict PA requirements from their insurance plan. This fragmentation means even experienced doctors often cannot predict whether a specific prescription will require prior authorization without submitting the request and waiting.
How Much Time Does Prior Authorization Add to Starting Dementia Treatment?
Prior authorization introduces delays that can range from a few days to several weeks. The fastest turnarounds occur when the patient clearly meets all insurance criteria and the doctor’s documentation is complete: in these cases, insurance companies sometimes approve within 24 to 48 hours. But the typical timeline is longer. Many insurance companies set a standard review period of three to five business days, and during that time the prescription cannot be filled and the patient cannot start the medication. These delays become problematic in the context of dementia treatment because early intervention is considered crucial for anti-amyloid drugs. Lecanemab is approved for mild cognitive impairment and mild dementia—early stages—because that is when the drug appears to have the most benefit.
If a patient is diagnosed with mild cognitive impairment in July, the neurologist prescribes lecanemab, and the insurance company takes ten days to approve it, then the patient waits another few days for the drug to be prepared and the first infusion scheduled, that patient has lost nearly three weeks of treatment. In a 78-week trial period, that might not seem significant, but every month without treatment represents progression of the underlying amyloid pathology. Some patients and families choose to appeal a prior authorization denial, which adds another 15 to 30 days. If the insurance company denies the initial request—perhaps because they determine the cognitive test scores do not meet their threshold—the doctor must gather additional information, write an appeal letter, and resubmit. During this time, the patient is still waiting, and treatment remains unavailable. A real example: a patient diagnosed with mild cognitive impairment in March receives a prescription for lecanemab that is denied on the grounds of insufficient evidence of amyloid pathology; the doctor appeals and provides the PET scan report, and the appeal is approved in May—two months after the original prescription.
What Can Caregivers and Patients Do to Speed Up Prior Authorization?
The most effective approach is to ensure the neurologist or prescribing doctor has all required documentation prepared before submitting the prior authorization request. This means having the cognitive testing, the brain imaging (MRI or PET scan showing amyloid), and any other relevant test results in the doctor’s office before the prescription is written. Caregivers can ask the neurologist’s office which tests are needed, schedule them proactively, and confirm that results are available before the doctor initiates the authorization process. This preparation phase can take weeks, but it eliminates delays after the prescription is submitted. Working directly with the insurance company’s pharmacy benefits manager (PBM) is also valuable. Many insurance plans have specialized departments for expensive or new drugs, and calling that department to ask about requirements before the doctor submits the prior authorization can clarify what documentation will be needed.
Some insurers provide expedited approval for patients who meet very clear criteria, and the doctor’s office can request expedited review when submitting the request. A patient’s advocacy or appeal can also matter: if the initial prior authorization is denied, asking the doctor to submit a detailed appeal letter with clinical rationale significantly improves approval rates compared to allowing the denial to stand. However, there is a major tradeoff: the time spent preparing documentation and managing prior authorization authorization is time that could be spent on other aspects of care. Caregivers are often managing appointments, medications, and escalating cognitive decline simultaneously, and navigating insurance requirements adds administrative burden. Some doctors’ offices are more experienced with prior authorization for dementia drugs and respond quickly; others may be unfamiliar with the process and cause additional delays. A comparison: a neurologist who specializes in cognitive disorders and manages many lecanemab authorizations can often get approval in three days, while a general practitioner prescribing lecanemab for the first time might take two weeks because they are less familiar with what the insurance company will request.
What Happens If Prior Authorization Is Denied?
Insurance companies deny prior authorization requests for dementia drugs for a variety of reasons. Some denials are based on clinical criteria: the patient’s cognitive test scores may fall outside the range that the insurance company considers appropriate for the drug, or the patient may have already progressed to moderate dementia, at which point the drug is not approved and not covered. Other denials reflect administrative issues: the prior authorization form may be incomplete, or the insurance company may claim that the test results are not recent enough (some plans require imaging within the last six months). Denial rates for lecanemab and other new dementia drugs vary by insurance company, but studies of early utilization show that prior authorization denials are common. Some Medicare Advantage plans have denied 30–40% of initial prior authorization requests for lecanemab, and rates of denial have been reported even higher in some state Medicaid programs.
When an initial request is denied, the appeal process typically allows the patient 30 to 60 days to gather additional information and resubmit. If the appeal is also denied, the patient is generally left without coverage for that medication. A critical limitation is that there is no standardized mechanism for appealing a denial beyond what the insurance company offers. Patients cannot go to an independent medical reviewer or a government agency if they disagree with the insurance company’s decision. Some patients and families pursue external reviews or file complaints with state insurance commissioners, but these processes are slow and rarely overturn denials in time to begin treatment promptly. A warning: if a patient is denied prior authorization for lecanemab due to cognitive scores, by the time an appeal is approved and treatment begins months later, the patient may have declined further, potentially moving out of the mild dementia range and no longer qualifying for the drug entirely.
Are There Alternative Ways to Access Dementia Drugs Without Prior Authorization?
Patients who are denied prior authorization or who face long delays sometimes explore alternative routes. Pharmaceutical companies offer patient assistance programs that can provide medications at reduced cost or free of charge to patients who cannot afford them or who are denied insurance coverage. Both lecanemab and donanemab have manufacturer assistance programs, and patients can apply directly to access the drug outside the insurance authorization process. However, these programs typically require proof of financial hardship or proof of insurance denial, and they still involve a separate approval process that can take days or weeks.
Clinical trials represent another pathway. Patients who do not meet insurance criteria or who cannot access the drug through their insurance plan may be enrolled in ongoing research trials studying dementia drugs, where the medication is provided free of charge. The limitation is that trial enrollment depends on specific eligibility criteria and trial site availability, and a patient may live far from a participating research center. An example: a patient denied prior authorization for lecanemab might be enrolled in a trial studying lecanemab combined with another therapy, gaining access to the drug while contributing data to research, but that trial may only be enrolling patients in three states, and the patient may not live in any of them.
How Does Prior Authorization Pressure Doctors to Practice Differently?
The prior authorization requirement for newer dementia drugs influences prescribing decisions in ways that extend beyond the individual patient. Some neurologists report that they avoid prescribing lecanemab or donanemab in their practice because they find the prior authorization process burdensome and are uncertain whether they will eventually receive approval. Instead, these doctors continue to prescribe older drugs like donepezil or memantine, which do not require prior authorization and have been standard treatment for decades, even though the newer drugs have shown greater efficacy in slowing cognitive decline. This creates a system where insurance company requirements, not clinical evidence, guide treatment choices.
Practices that do prescribe these newer drugs must invest staff time in managing authorizations: administrative staff spend hours following up with insurance companies, resubmitting denied requests, and calling for status updates. A real example: a neurology practice in a mid-sized city serves 50 patients with mild cognitive impairment who might be candidates for lecanemab in any given year. Prior authorization for those 50 patients requires approximately 100 to 150 hours of staff time annually—calling the insurance companies, resubmitting paperwork after denials, and tracking approval status. That same staff time could be spent on patient education, follow-up cognitive testing, or other direct care activities, but instead it is consumed by administrative requirements. The consequence is that resource-limited practices may effectively ration access to newer dementia drugs not because they lack efficacy, but because the authorization burden makes them impractical to prescribe at scale.
- —
Frequently Asked Questions
How long does prior authorization typically take for lecanemab?
Most insurance companies complete initial review within 3–5 business days, but some take up to 2 weeks. If the request is denied and appealed, the full process can extend to 30–60 days.
Can a doctor prescribe lecanemab before prior authorization is approved?
No. Pharmacies cannot dispense the drug without prior authorization approval or proof of payment; doctors cannot legally write a prescription that the patient can fill without insurance approval or out-of-pocket payment at full price.
What should I do if my insurance denies prior authorization for a dementia drug?
Ask your doctor to submit a detailed appeal with additional clinical documentation. If the appeal is also denied, ask about patient assistance programs from the manufacturer or whether you qualify for a clinical trial.
Does Medicare require prior authorization for lecanemab and other new dementia drugs?
Medicare coverage varies by plan type. Original Medicare (Parts A and B) covers lecanemab, but rules differ by state and change frequently. Medicare Advantage plans and Part D drug plans often require prior authorization.
Can I pay out of pocket to avoid prior authorization?
Yes, but lecanemab costs approximately $26,500 per year, and donanemab costs similarly. Most patients cannot pay this amount without insurance, so avoiding prior authorization by self-paying is not practical for most families. —
